IM Cannabis (IMCC) Stock Price, News & Analysis

Company Overview

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners.

Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.

Key Stats

• Today's Range: $2.01 to $2.19
• 50-Day Range: $1.77 to $2.93
• 52-Week Range: $1.29 to $7.12
• Volume: 139,673 shs
• Average Volume: 71,204 shs
• Market Capitalization: $10.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

IMCC Stock Analysis - Frequently Asked Questions

How have IMCC shares performed this year?

IM Cannabis' stock was trading at $2.33 on January 1st, 2025. Since then, IMCC stock has decreased by 13.3% and is now trading at $2.02.

How were IM Cannabis' earnings last quarter?

IM Cannabis Corp. (NASDAQ:IMCC) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.07. The business earned $9.21 million during the quarter, compared to analyst estimates of $12.88 million. IM Cannabis had a negative net margin of 4.19% and a negative trailing twelve-month return on equity of 59.80%.

When did IM Cannabis' stock split?

IM Cannabis shares reverse split on Friday, July 12th 2024.The 1-6 reverse split was announced on Friday, July 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of IM Cannabis?

Shares of IMCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IM Cannabis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IM Cannabis investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), GE Aerospace (GE) and AppLovin (APP).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMCC
• CIK: 1792030
• Web: www.imcannabis.com
• Phone: 972-54-433-1111
• Fax: N/A
• Employees: 340
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.72 million
• Net Margins: -4.19%
• Pretax Margin: -4.55%
• Return on Equity: -59.80%
• Return on Assets: -5.15%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 0.72
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $39.44 million
• Price / Sales: 0.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.03 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 5,250,000
• Free Float: N/A
• Market Cap: $11.05 million
• Optionable: Not Optionable
• Beta: 2.13